Stimulation of synaptoneurosome glutamate release by monomeric and fibrillated α‐synuclein

The α‐synuclein protein exists in vivo in a variety of covalently modified and aggregated forms associated with Parkinson's disease (PD) pathology. However, the specific proteoform structures involved with neuropathological disease mechanisms are not clearly defined. Since α‐synuclein plays a r...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroscience research Vol. 95; no. 9; pp. 1871 - 1887
Main Authors: Sarafian, Theodore A., Littlejohn, Kaitlyn, Yuan, Sarah, Fernandez, Charlene, Cilluffo, Marianne, Koo, Bon‐Kyung, Whitelegge, Julian P., Watson, Joseph B.
Format: Journal Article
Language:English
Published: United States Wiley 01-09-2017
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The α‐synuclein protein exists in vivo in a variety of covalently modified and aggregated forms associated with Parkinson's disease (PD) pathology. However, the specific proteoform structures involved with neuropathological disease mechanisms are not clearly defined. Since α‐synuclein plays a role in presynaptic neurotransmitter release, an in vitro enzyme‐based assay was developed to measure glutamate release from mouse forebrain synaptoneurosomes (SNs) enriched in synaptic endings. Glutamate measurements utilizing SNs from various mouse genotypes (WT, over‐expressers, knock‐outs) suggested a concentration dependence of α‐synuclein on calcium/depolarization‐dependent presynaptic glutamate release from forebrain terminals. In vitro reconstitution experiments with recombinant human α‐synuclein proteoforms including monomers and aggregated forms (fibrils, oligomers) produced further evidence of this functional impact. Notably, brief exogenous applications of fibrillated forms of α‐synuclein enhanced SN glutamate release but monomeric forms did not, suggesting preferential membrane penetration and toxicity by the aggregated forms. However, when applied to brain tissue sections just prior to homogenization, both monomeric and fibrillated forms stimulated glutamate release. Immuno‐gold and transmission electron microscopy (TEM) detected exogenous fibrillated α‐synuclein associated with numerous SN membranous structures including synaptic terminals. Western blots and immuno‐gold TEM were consistent with SN internalization of α‐synuclein. Additional studies revealed no evidence of gross disruption of SN membrane integrity or glutamate transporter function by exogenous α‐synuclein. Overall excitotoxicity, due to enhanced glutamate release in the face of either overexpressed monomeric α‐synuclein or extrasynaptic exposure to fibrillated α‐synuclein, should be considered as a potential neuropathological pathway during the progression of PD and other synucleinopathies. © 2017 Wiley Periodicals, Inc. The proteoform structures of α‐synuclein that modulate presynaptic neurotransmitter release in Parkinson's disease (PD) pathology are not clearly defined. In this study, an in vitro enzyme‐based assay was used to measure glutamate release from mouse forebrain synaptoneurosomes (SNs) utilizing various mouse genotypes and reconstituted human α‐synuclein proteoforms (monomers, oligomers, fibrils). Notably, exogenous applications (SN Treated) of fibrillated forms of α‐synuclein preferentially enhanced glutamate release, lending support to synaptic excitotoxicity as a neuropathological pathway during the progression of PD and other synucleinopathies.
Bibliography:This work was funded by the UCSD/UCLA Diabetes Research Center (P30 DK063491), to JPW. The UCLA‐DOE Protein Expression Technology Center was supported by the U.S. Department of Energy, Office of Biological and Environmental Research (BER) program, award number DE‐FC02‐02ER63421.
SIGNIFICANCE How the α‐synuclein protein becomes toxic to neuronal communication in Parkinson's disease remains unclear. The current study showed that aggregated forms of α‐synuclein were preferentially taken up by synaptic terminals and abnormally released elevated amounts of the neurotransmitter glutamate.
JNR-2016-May-6760
UCSD
FC02-02ER63421; P30 DK063491
USDOE Office of Science (SC), Biological and Environmental Research (BER)
ISSN:0360-4012
1097-4547
DOI:10.1002/jnr.24024